L12.35
Other acquired epidermolysis bullosa
Clinical Classification Guidelines
Medical Intelligence & Overview
Other acquired epidermolysis bullosa is a rare skin condition characterized by fragile skin that blisters easily, often resulting from external trauma or certain medical treatments. Unlike genetic forms of the disease, this type develops later in life due to acquired factors. It leads to skin blistering and erosions, which can cause discomfort and increase susceptibility to infections. Awareness and management focus on protecting the skin and preventing further injury.
Causes & Symptoms
Clinical Causes: Exposure to certain chemicals or irritants causing skin fragility Reactive responses to specific medications or treatments Underlying autoimmune conditions that affect skin strength Infections that compromise skin integrity Physical trauma or repeated friction Environmental factors like extreme heat or cold
Key Symptoms: Blistering of the skin in response to minor injury or pressure Erosions or open sores on the skin Fragile skin that tears easily Redness or inflammation around affected areas Pain or discomfort in blistered regions Potential secondary infections due to skin breaches
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical examination and patient history. A dermatologist may perform a skin biopsy to examine tissue samples under a microscope, helping to distinguish acquired forms from inherited types. Additional tests, such as immunofluorescence mapping, may be used to identify immune system involvement and rule out other skin conditions. Proper diagnosis is essential for developing an effective management plan.
Treatment Protocols: Managing acquired epidermolysis bullosa focuses on minimizing skin trauma and promoting healing. Common approaches include:
Clinical Advice & FAQs
Billing Guidance
Is L12.35 a billable ICD-10 code?
Yes, L12.35 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report L12.35?
Clinical documentation must specify the nature of Other acquired epidermolysis bullosa and any associated comorbidities for accurate reporting.
Cite this Clinical Reference